Clinical trials: Oligodendroglioma, Anaplastic
Brain Tumors, Metastatic Disease
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors.
- Trial name
- NCT00369785
- Testing
- donepezil hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 198 people
- Sponsor
- Wake Forest University Health Sciences
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma
- Trial name
- NCT00430079
- Testing
- etanidazole, conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Brachytherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Brachytherapy uses radioactive material to kill cancer cells remaining after surgery. PURPOSE: Phase I trial to study the effectiveness of brachytherapy in treating patients who have recurrent malignant glioma.
- Trial name
- NCT00045474
- Testing
- adjuvant therapy, iodine I 125
- Where
- 9 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
CCI-779 in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CCI-779 in treating patients who have malignant…
- Trial name
- NCT00022724
- Testing
- temsirolimus
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO)
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
This trial is designed to evaluate safety and explore possible efficacy of 5-aminolevulinic acid hydrochloride (5-ALA HCl, Gliolan®) with CV01 delivery of ultrasound for sonodynamic therapy in patients with newly diagnosed…
- Conditions
- Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM)
- Trial name
- NCT06665724
- Testing
- 5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Universität Münster
CNS Cancer, CNS BRAIN
Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment.
- Trial name
- NCT00588523
- Testing
- temozolomide followed by high dose busulfan and thiotepa
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Low Grade Glioma, Glioblastoma Multiforme
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
Background: The blood-brain barrier helps to protect the central nervous system (brain and spinal cord) from harmful toxins, but also prevents potentially useful chemotherapy from reaching brain tumors.
- Conditions
- Low Grade Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01281982
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent…
- Trial name
- NCT00004041
- Testing
- Ad5CMV-p53 gene, conventional surgery
- Where
- 8 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma
- Trial name
- NCT00919750
- Testing
- Cytology Specimen Collection Procedure
- Where
- 187 sites in United States, Australia and 4 more
- Volunteers
- 1,258 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers
RATIONALE: Yoga, meditation, and breathing exercises may help lower stress and improve quality of life in patients with malignant brain tumors and their family caregivers.
- Trial name
- NCT00376818
- Testing
- exercise intervention, educational intervention, physiologic testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Anaplastic Astrocytoma, Anaplastic Ependymoma
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma
- Trial name
- NCT01836549
- Testing
- imetelstat sodium
- Where
- 11 sites in United States
- Volunteers
- 43 people
- Sponsor
- Pediatric Brain Tumor Consortium
Anaplastic Astrocytoma, Anaplastic Ependymoma
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
This pilot phase I clinical trial studies how well lapatinib ditosylate before surgery works in treating patients with high-grade glioma that has come back after a period of time during which the tumor could not be detected.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma
- Trial name
- NCT02101905
- Testing
- Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01478321
- Testing
- Temozolomide, hypofractionated radiation therapy, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Northwestern University
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy.
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma
- Trial name
- NCT00042991
- Testing
- gefitinib, radiation therapy, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)